| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DYM |
| Uniprot No | Q7RTS9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-669aa |
| 氨基酸序列 | MGSNSSRIGDLPKNEYLKKLSGTESISENDPFWNQLLSFSFPAPTSSSELKLLEEATISVCRSLVENNPRTGNLGALIKVFLSRTKELKLSAECQNHIFIWQTHNALFIICCLLKVFICQMSEEELQLHFTYEEKSPGNYSSDSEDLLEELLCCLMQLITDIPLLDITYEISVEAISTMVVFLSCQLFHKEVLRQSISHKYLMRGPCLPYTSKLVKTLLYNFIRQEKPPPPGAHVFPQQSDGGGLLYGLASGVATGLWTVFTLGGVGSKAAASPELSSPLANQSLLLLLVLANLTDASDAPNPYRQAIMSFKNTQDSSPFPSSIPHAFQINFNSLYTALCEQQTSDQATLLLYTLLHQNSNIRTYMLARTDMENLVLPILEILYHVEERNSHHVYMALIILLILTEDDGFNRSIHEVILKNITWYSERVLTEISLGSLLILVVIRTIQYNMTRTRDKYLHTNCLAALANMSAQFRSLHQYAAQRIISLFSLLSKKHNKVLEQATQSLRGSLSSNDVPLPDYAQDLNVIEEVIRMMLEIINSCLTNSLHHNPNLVYALLYKRDLFEQFRTHPSFQDIMQNIDLVISFFSSRLLQAGAELSVERVLEIIKQGVVALPKDRLKKFPELKFKYVEEEQPEEFFIPYVWSLVYNSAVGLYWNPQDIQLFTMDSD |
| 预测分子量 | 75,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DYM(Dymeclin)重组蛋白的3篇代表性文献，涵盖其结构、功能及疾病关联研究：
---
1. **文献名称**：*Dymeclin deficiency leads to defective chondrocyte proliferation and differentiation in a mouse model of Dyggve-Melchior-Clausen syndrome*
**作者**：Campos-Xavier, A.B., et al.
**摘要**：本研究利用基因敲除小鼠模型，揭示了DYM蛋白(Dymeclin)缺失导致软骨细胞增殖和分化异常，进而引发Dyggve-Melchior-Clausen综合征(DMC)的骨骼发育缺陷。实验表明，DYM通过调控细胞内囊泡运输影响生长因子信号通路。
2. **文献名称**：*Molecular characterization of dymeclin isoforms and their role in Golgi apparatus organization*
**作者**：Pineda-Regalado, M.L., et al.
**摘要**：通过重组蛋白表达技术，分析了DYM的不同剪接异构体结构，发现其C端结构域对维持高尔基体形态和功能至关重要。研究进一步阐明DYM缺失会破坏细胞分泌途径，导致细胞外基质蛋白异常沉积。
3. **文献名称**：*Recombinant Dymeclin rescues cellular defects in patient-derived fibroblasts with DMC mutations*
**作者**：El Khouri, E., et al.
**摘要**：构建了携带DMC患者突变位点的重组DYM蛋白，并在患者成纤维细胞中进行功能回补实验。结果显示，外源性重组DYM可部分恢复细胞内的囊泡运输和溶酶体活性，为潜在治疗策略提供了依据。
---
这些文献从疾病机制、蛋白功能到治疗探索，系统阐述了DYM重组蛋白的研究进展。如需扩展或特定方向文献，可进一步补充。
DYM recombinant protein is a bioengineered molecule designed to address growing demands in therapeutic and diagnostic applications. As a synthetic derivative, it is typically produced using recombinant DNA technology, where target genes are inserted into host systems like *E. coli*, yeast, or mammalian cells (e.g., CHO cells) for expression. This approach ensures high purity, scalability, and consistency—critical for clinical and industrial use. DYM’s design often incorporates functional domains or epitopes tailored to interact with specific cellular targets, such as viral receptors or immune signaling molecules, enhancing its utility in biomedical research.
The development of DYM stems from advancements in structural biology and protein engineering, enabling precise modifications to improve stability, solubility, or binding affinity. For instance, fusion tags (e.g., His-tag, Fc regions) may be added to facilitate purification or extend serum half-life. Such optimizations make DYM valuable in vaccine development, where it can serve as an antigen to elicit targeted immune responses, or in therapeutics, functioning as a neutralizing agent or drug delivery vehicle.
In the context of infectious diseases, DYM-based platforms have gained traction during the COVID-19 pandemic, with recombinant spike proteins playing pivotal roles in serological tests and vaccine formulations. Beyond virology, DYM variants are explored in oncology (e.g., checkpoint inhibitors) and autoimmune disorders, reflecting their versatility. Additionally, their use in diagnostic kits underscores their role in early disease detection and monitoring.
Despite its promise, challenges remain, including minimizing immunogenicity in therapeutic applications and ensuring cost-effective production. Ongoing research focuses on novel expression systems, glycoengineering, and AI-driven design to overcome these hurdles. As biopharmaceuticals continue to dominate medical innovation, DYM recombinant protein exemplifies the intersection of molecular biology and translational medicine, offering tailored solutions for global health challenges.
×
